AI Medical Technology: A Rising Leader, One Year Later

 
• By Barnaby Pickering
  
Generate a summary of this article
Listen to this article
Beta

AI Medical Technology has been busy, with publications demonstrating its lead product’s potential in melanoma, ongoing fundraising and board appointments.  

AI MEDICAL TECHNOLOGY'S DERMALYSER AIMS TO GIVE DOCTORS MORE CONFIDENCE WHEN MAKING DECISIONS • Source: Shutterstock

Since being nominated as one of In Vivo’s rising leaders a year ago, Christoffer Ekström has overseen several key developments at his company, AI Medical Technology.

Lead Product 

AI Medical Technology’s lead product is its Dermalyser platform, which uses artificial intelligence to transform a smartphone into a powerful tool for the diagnosis of melanoma. A clinician uses dermalyser in conjunction with a dermatoscope placed in front of their smartphone camera. They take a picture of a lesion of concern, and Dermalyzer provides a diagnostic recommendation in just a few seconds.

2023 saw the appointment of two new board members to the company. Peter Löwendahl joined in March, and has been...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Rising Leaders

Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future clone3

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By Saba Afreen

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

In Vivo’s 2026 Rising Leaders

 
• By Saba Afreen

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

More from Leadership

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By Saba Afreen

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

In Vivo’s 2026 Rising Leaders

 
• By Saba Afreen

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.